Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: Effects of methoxsalen, a CYP2A5/6 inhibitor

Nicotine and Tobacco Research

Volumn 16, Issue 1, 2014, Pages 18-25

  Alsharari, Shakir D ^a   Siu, Eric C K ^b   Tyndale, Rachel F ^b   Damaj, Mohamad Imad ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF TORONTO   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECAMYLAMINE; METHOXSALEN; NICOTINE; COTININE; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; HOT PLATE TEST; HYPOTHERMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; TAIL FLICK TEST; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG INTERACTION; INTRAPERITONEAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; COTININE; DRUG INTERACTIONS; INJECTIONS, INTRAPERITONEAL; MALE; METHOXSALEN; MICE; NICOTINE; TANDEM MASS SPECTROMETRY;

EID: 84901373672     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntt105     Document Type: Article

References (36)

1. AlSharari, S. D., Akbarali, H. I., Abdullah, R. A., Shahab, O., Auttachoat, W., Ferreira, G. A., & Damaj, M. I. (2012). Novel insights on the effect of nicotine in a murine colitis model. Journal Pharmacology Experimental Therapeutics, 344, 207-217. doi:10.1124/jpet.112.198796
2. Benowitz, N. L., Jacob P, III, Denaro, C., & Jenkins, R. (1991). Stable isotope studies of nicotine kinetics and bioavailability. Clinical Pharmacology Therapeutics, 49, 270-277. doi:10.1038/clpt.1991.28
3. Benowitz, N. L., Pérez-Stable, E. J., Herrera, B., & Jacob, P. III. (2002). Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. Journal National Cancer Institute, 94, 108-115.
4. Benowitz, N. L., Zevin, S., & Jacob, P. III. (1997). Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. British Journal Clinical Pharmacology, 43, 259-267.
5. Buchhalter, A. R., Fant, R. V., & Henningfield, J. E. (2008). Novel pharmacological approaches for treating tobacco dependence and withdrawal: Current status. Drugs, 68, 1067-1088.
6. Collins, A. C., Pogun, S., Nesil, T., & Kanit, L. (2012). Oral nicotine self-administration in rodents. Journal Addiction Research Therapy, S2. doi:pii: 004.
7. Compton, R. F., Sandborn, W. J., Lawson, G. M., Sheets, A. J., Mays, D. C., Zins, B. J., & Green, J. (1997). A doseranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Alimentary Pharmacology Therapeutics, 11, 865-874. doi:10.1046/j.1365-2036.1997.00236.x
8. Damaj, M. I., Siu, E. C., Sellers, E. M., Tyndale, R. F., & Martin, B. R. (2007). Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. Journal Pharmacology Experimental Therapeutics, 320, 250-257. doi:10.1124/jpet.106.111237
9. D'Orlando, K. J., & Fox, B. S. (2004). Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tobacco Research, 6, 63-70. doi:10.1080/146222 00310001656876
10. Fernandez-Salguero, P., Hoffman, S. M., Cholerton, S., Mohrenweiser, H., Raunio, H., & Rauto, A. (1995). A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variation CYP2A6 alleles. American Journal of Human Genetics, 57, 651-660.
11. Gäddnäs, H., Pietilä, K., & Ahtee, L. (2000). Effects of chronic oral nicotine treatment and its withdrawal on locomotor activity and brain monoamines in mice. Behavioral Brain Research, 113, 65-72.
12. Grabus, S. D., Martin, B. R., Batman, A. M., Tyndale, R. F., Sellers, E., & Damaj, M.I. (2005). Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl), 178, 183-192. doi:org/10.1007/s00213-004-2007-3
13. Henningfield, J. E., & Keenan, R. M. (1993). Nicotine delivery kinetics and abuse liability. Journal Consulting Clinical Psychology, 61, 743-750.
14. Ho, M. K., Mwenifumbo, J. C., Al Koudsi, N., Okuyemi, K. S., Ahluwalia, J. S., Benowitz, N. L., & Tyndale, R. F. (2009). Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology and Therapeutics, 85, 635-643.
15. Lerman, C., Jepson, C., Wileyto, E. P., Patterson, F., Schnoll, R., Mroziewicz, M., Benowitz, N., & Tyndale, R. F. (2010). Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology and Therapeutics, 87, 553-557.
16. Lerman, C., Tyndale, R. F., Patterson, F., Wileyto, E. P., Pinto, A., & Benowitz, N. (2006). Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics, 79, 600-608.
17. Locklear, L. L., McDonald, C. G., Smith, R. F., & Fryxell, K. J. (2012). Adult mice voluntarily progress to nicotine dependence in an oral self-selection assay. Neuropharmacology, 63, 582-592. doi:10.1016/j.neuropharm.2012.04.037
18. Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005). Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology Therapeutics, 77, 145-158.
19. Messina, E. S., Tyndale, R. F., & Sellers, E. M. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal Pharmacology Experimental Therapeutics, 282, 1608-1614.
20. Murphy, S. E., Raulinaitis, V., & Brown, K. M. (2005). Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug Metabolism Disposition, 33, 1166-1173. doi:10.1124/dmd.105.004549
21. Mwenifumbo, J. C., & Tyndale, R. F. (2009). Molecular genetics of nicotine metabolism. Handbook Experimental Pharmacology, 192, 235-259.
22. Nakayama, H., Okuda, H., Nakashima, T., Imaoka, S., & Funae, Y. (1993). Nicotine metabolism by rat hepatic cytochrome P450s. Biochemical Pharmacology, 45, 2554-2556. doi:10.1016/0006-2952(93)90238-R
23. Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J., & Tsutsui, M. (1996). Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
24. Patterson, F., Schnoll, R. A., Wileyto, E. P., Pinto, A,. Epstein, L. H., Shields, P. G., Hawk, L. W., Tyndale, R. F., Benowitz, N., & Lerman, C. (2008). Toward personalized therapy for smoking cessation: A randomized placebo-controlled trial of bupropion. Clinical Pharmacology and Therapeutics, 84, 320-325.
25. Ray, R., Tyndale, R. F., & Lerman, C. (2009). Nicotine dependence pharmacogenetics: Role of genetic variation in nicotine metabolizing enzymes. Journal of Neurogenetics, 23, 1-10.
26. Rowell, P. P., Hurst, H. E., Marlowe, C., Bennett, B. D. (1983). Oral administration of nicotine: Its uptake and distribution after chronic administration to mice. Journal of Pharmacological Methods, 9, 249-261.
27. Schoedel, K. A., Sellers, E. M., & Tyndale, R.F. (2001). Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemical Pharmacology, 62, 1025-1036. doi:10.1016/S0006-2952(01)00744-4
28. Sellers, E. M., Kaplan, H. L., & Tyndale, R.F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology Therapeutics, 68, 35-43. doi:10.1067/mcp.2000.107651
29. Siu, E. C., Wildenauer, D. B., & Tyndale, R. F. (2006). Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl), 184, 401-408. doi:10.1007/s00213-006-0306-6
30. Svensson, C. K. (1987). Clinical pharmacokinetics of nicotine. Clinical Pharmacokinetics, 12, 30-40.
31. Tyndale, R. F., Li, Y., Kaplan, H. L., & Seller, E. M. (1999). Inhibition of nicotine's metabolism: A potential new treatment for tobacco dependence. Clinical Pharmacology Therapeutics, 65, 145. doi:10.1016/S0009-9236(99)80112-X
32. Tallarida, R.J., & Murray, R.B. (1987) Manual of pharmacological calculations with computer programs New York: Springer-Verlag.
33. Westman, E. C., Tomlin, K. F., Perkins, C. E., & Rose, J.E. (2001). Oral nicotine solution for smoking cessation: A pilot tolerability study. Nicotine Tobacco Research, 3, 391-396. doi:10.1080/14622200126973
34. Wilking, J. A., Hesterberg, K. G., Nguyen, V. H., Cyboron, A.P., Hua, A.Y., & Stitzel, J.A. (2012). Comparison of nicotine oral consumption and baseline anxiety measures in adolescent and adult C57BL/6J and C3H/Ibg mice. Behavioral Brain Research, 233, 280-287. doi:10.1016/j. bbr.2012.05.022
35. Zhang, W., Kilicarslan, T., Tyndale, R. F., & Sellers, E. M. (2001). Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism Disposition, 29, 897-902. http://dmd.aspetjournals.org/content/29/6/897.
36. Zins, B. J., Sandborn, W. J., Mays, D. C., Lawson, G. M., McKinney, J. A., Tremaine, W. J., & Lipsky, J. J. (1997). Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal Clinical Pharmacology, 7, 426-436. Retrieved from www. ncbi.nlm.nih.gov/pubmed/9156375